Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC
Sign Up to like & getrecommendations! Published in 2024 at "NPJ Breast Cancer"
DOI: 10.1038/s41523-024-00679-7
Abstract: In the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy among patients with previously untreated locally… read more here.
Keywords: plus chemotherapy; pembrolizumab plus; placebo; keynote 355 ... See more keywords